Total rubbish that they can surreptitiously turn a Phase 1b stand alone trial (planned) to be followed by a Phase 2 trial (some) of whose parameters will be determined by Phase 1b results, into a combined Phase 1b/2 trial.
Absolutely no way they can get out of reporting at least top line Phase 1b results particularly wrt their influence on Phase 2 design.
Shareholders MUST be informed. Otherwise I (along with the bulk of 'in the dark' shareholders, I would hope) will be making strong representations to ASIC in an attempt to force their hand.
The whole idea is ludicrous.
Clinical Trial Website Update, page-31
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.7¢ | $388.1K | 10.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 146314 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 2536521 | 6 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
